Navigation Links
Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk
Date:7/31/2014

Toledo, Ohio (PRWEB) July 31, 2014

In a front-page story, the Wall Street Journal (7/30) reports that the pharmaceutical giant, Johnson & Johnson, is withdrawing its laparoscopic power morcellator due to data showing that it can spread undetected cancer. This important story has also been reported by Bloomberg News (7/31), Reuters (7/30), USA Today (7/31), the AP (7/30), the Pittsburgh Business Times (7/30) and TIME (7/30).

The morcellator tool is used during uterine procedures to, “slice up common uterine masses called fibroids, and uteruses themselves, into fragments so they can be removed in minimally invasive surgery.” (Wall Street Journal, 7/30)

J&J previously suspended the sale of new morcellators in April after the U.S. Food and Drug Administration issued a safety communication advising doctors not to use the tool. Specifically, FDA concluded that, “based on an analysis of currently available data, it poses a risk of spreading unsuspected cancerous tissue, notably uterine sarcomas, beyond the uterus.”

The FDA determined that approximately 1 in 350 women who are undergoing hysterectomy or myomectomy for fibroids have an unsuspected type of uterine cancer called uterine sarcoma. It further noted, “If laparoscopic power morcellation is performed in these women, there is a risk that the procedure will spread the cancerous tissue within the abdomen and pelvis, significantly worsening the patient’s likelihood of long-term survival.”

According to an article published in the Journal of the American Medical Association in March, more than 20,000 minimally invasive or robotic hysterectomies are done annually.

The law firm of Zoll, Kranz & Borgess, LLC (“ZKB”) devotes its practice to the field of pharmaceutical and medical device litigation. ZKB is dedicated to compelling companies to produce safer products. Injured clients and partnering attorneys from across the U.S. appreciate and rely upon over 70 years of combined experience in pharmaceutical mass torts and multidistrict litigation. ZKB’s experienced team includes a practicing physician-attorney and all the technology, knowledge and experience necessary to succeed in this complex legal field.

For more information about morcellators or if you were diagnosed with cancer after a hysterectomy or myomectomy (removal of uterine fibroids) using a power morcellator device, contact ZKB toll-free at (888) 841-9623 or visit the firm’s website at http://www.zkblaw.com. Initial consultations are always free and confidential.

SOURCES
Wall Street Journal (7/30) http://online.wsj.com/articles/johnson-johnson-to-call-for-voluntary-return-of-morcellators-1406754350

FDA News Release (4/17/14)
http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm393689.htm

JAMA: Evaluating the Risks of Electric Uterine Morcellation (March 2014)
http://jama.jamanetwork.com/article.aspx?articleid=1828692

Read the full story at http://www.prweb.com/releases/fibroid-hysterectomy/morcellator-cancer-risk/prweb12062687.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Study examines presence of uterine cancers at the time of hysterectomy using morcellation
2. Women’s Excellence Physicians Perform Successful Robotic Laparoscopic Hysterectomy to Remove 16 Week-Sized Fibroid Uterus; Small Incisions and Quick Recovery Result
3. Study Says Using the da Vinci Surgical Robot for a Hysterectomy Fails to Cut Complications and May Raise Pneumonia Risk, Notes Parker Waichman LLP
4. Da Vinci Robot Lawsuit Lawyers at Wright & Schulte LLC Disturbed by New Study Examining Risks and Benefits of Robotic Surgery Hysterectomy
5. Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on New Study Findings that Casts Doubt on Robot-Assisted Hysterectomy
6. Piece of da Vinci Surgical Robot Instrument Breaks off Inside Woman During Hysterectomy; It’s Found Following Months of Suffering, Parker Waichman LLP Notes
7. Johns Hopkins surgeons among the first in the country to perform a robotic single-site hysterectomy
8. Hysterectomy May Not Raise Heart Risks After All: Study
9. Estrogen helps keep joint pain at bay after hysterectomy
10. Robotic Surgery for Hysterectomy Often Not Best Option, Ob/Gyn Group Says
11. Delaying radiation therapy after hysterectomy ups risk of uterine cancer recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
Breaking Medicine Technology: